After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound

Why It Matters

The projected EBITDA inflection signals Tempus AI may finally achieve sustainable profitability, a critical catalyst for investors and the broader health‑tech AI market.

Key Takeaways

• Q4 revenue up 83% to $367 million, strong growth
• Adjusted EBITDA flips positive, $12.9 million versus prior loss
• 450‑petabyte data moat hinders AI competitors' entry
• Net retention 126% indicates strong customer upsell
• Analysts forecast 40%+ upside, targeting $79‑$100 price

Pulse Analysis

Tempus AI sits at the intersection of artificial intelligence and precision medicine, leveraging a 450‑petabyte multimodal dataset that rivals the total imaging output of the U.S. healthcare system. This data reservoir not only fuels the company’s proprietary models but also creates a formidable barrier to entry for rivals lacking comparable testing volume. As hospitals and oncologists increasingly demand AI‑enhanced diagnostics, Tempus’s entrenched relationships with over 8,500 oncologists position it as a critical infrastructure provider in the evolving digital health ecosystem.

Financially, Tempus has demonstrated a dramatic turnaround. Q4 2025 revenue surged 83% to $367 million, driven by both acquisitions and robust organic growth of 33.5%. More importantly, adjusted EBITDA swung to a positive $12.9 million, reversing a $7.8 million loss a year earlier. Management’s guidance for 2026 anticipates 25% revenue expansion and a full‑year adjusted EBITDA of $65 million, marking the company’s first profitable year on an adjusted basis. This earnings inflection, coupled with a net retention rate of 126%, underscores the durability of its recurring revenue streams and the effectiveness of its upsell strategy.

Analyst sentiment reflects optimism tempered by recent target reductions. Consensus price forecasts range from $79 to $100, implying upside potential of 30‑50% from current levels. While the stock remains volatile, the combination of a unique data moat, improving profitability metrics, and strong customer retention creates a compelling case for a rebound. Investors should weigh the upside against execution risks, such as integration of recent acquisitions and the competitive pressure from larger AI players entering healthcare, but the fundamentals suggest Tempus AI could be poised for a notable recovery.